Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
anemia
Biotech
Disc spins faster by paying Mabwell $10M for blood disorder drug
Disc has come a step closer to getting a third blood disorder candidate into the clinic via a licensing deal with Mabwell worth $10 million upfront.
James Waldron
Jan 20, 2023 7:21am
Bluebird's sickle cell trial in under-18s back after year hold
Dec 19, 2022 10:55am
Akebia is taking the fight to the FDA months after rejection
Nov 4, 2022 12:02pm
Akebia's anemia drug just misses in a COVID-19 trial
Aug 5, 2022 10:14am
After dispute, Otsuka pays Akebia $55M to exit anemia pill pacts
Jul 1, 2022 8:15am
Roivant decants another Vant armed with Eisai blood cancer drug
Feb 14, 2022 8:45am